rheumatoid arthritis

Showing 15 posts of 66 posts found.


NHS in Scotland makes rheumatoid arthritis drug available

September 14, 2021
Manufacturing and Production Galapagos UK, NHS, Scotland, filgotinib, rheumatoid arthritis

The Scottish Medicines Consortium (SMC) have recommended the use of Galapagos UK’s JYSELECA® (filgotinib) for eligible patients with severe active …

NICE release new guidance on rheumatoid arthritis treatment

June 10, 2021
NICE, biosimilar, rheumatoid arthritis

NICE has today published final draft guidance for the treatment of moderate rheumatoid arthritis in patients who have not responded …


AbbVie’s rheumatoid arthritis drug Rinvoq approved for NHS Scotland

February 9, 2021
Manufacturing and Production AbbVie, rheumatoid arthritis

The Scottish Medicines Consortium (SMC) has recommended AbbVie’s rheumatoid arthritis (RA) drug Rinvoq (upadacitinib) for use on the NHS in …


Celltrion’s Humira biosimilar is comparable in treating rheumatoid arthritis

November 4, 2020
Research and Development Humira, biosimilar, celltrion, rheumatoid arthritis

Celltrion has revealed new Phase 3 data demonstrating that its high concentration (100mg/mL) and citrate-free biosimilar CT-P17 proved comparable to …


AbbVie granted EU marketing authorisation for new arthritis drug

December 19, 2019
Business Services AbbVie, EC, EU, arthritis, rheumatoid arthritis

AbbVie have announced that the European Commission (EC) have granted marketing authorisation for RINVOQ (upadacitnib). It’s a daily selective reversible …


AbbVie scoops up FDA approval for Rinvoq in moderately to severely active rheumatoid arthritis

August 19, 2019
Sales and Marketing AbbVie, FDA, Rinvoq, pharma, rheumatoid arthritis

The FDA has awarded marketing authorisation to AbbVie’s Rinvoq (upadacitinib) for the treatment of moderately to severely active rheumatoid arthritis, …

Pfizer overhauls Xeljanz study over concerns of increased risk of pulmonary embolism and death

February 21, 2019
Research and Development Pfizer, Xeljanz, pharma, rheumatoid arthritis

Pfizer is set to overhaul the dosing groups in its ongoing study of Xeljanz (tofacitinib) after an evaluation from a …


Amgen biosimilar proves non-inferior to J&J’s Remicade in rheumatoid arthritis

June 27, 2018
Research and Development, Sales and Marketing Amgen, Johnson & Jonson, Remicade, pharma, rheumatoid arthritis

Amgen has unveiled new Phase 3 data for its biosimilar version of Johnson & Johnson’s Remicade (infliximab), confirming that it …

Lilly’s arthritis drug hits trouble at FDA committee

April 24, 2018
Manufacturing and Production, Sales and Marketing Eli Lilly, Incyte, biotech, drugs, pharma, pharmaceutical, rheumatoid arthritis

FDA’s advisory committee were openly conflicted about deciding on the safety of Eli Lilly and Incyte’s drug, baricitinib, for the …

Lilly and Incyte’s resubmission of arthritis drug data fails to assuage FDA concerns

April 20, 2018
Medical Communications, Sales and Marketing Eli Lilly, FDA, Incyte, baricitinib, pharma, rheumatoid arthritis

Eli Lilly and Incyte are facing more complications in the US approval of their experimental rheumatoid arthritis (RA) drug baricitinib …


AbbVie’s rheumatoid arthritis drug bests even its own blockbuster Humira at Phase 3

April 11, 2018
Research and Development AbbVie, Humira, pharma, rheumatoid arthritis, upadacitinib

AbbVie posted a strong showing this week from its JAK1 inhibitor upadacitinib, indicating that the drug outperformed even its own …


Death in trial blackens AbbVie’s positive rheumatoid arthritis data

December 21, 2017
Research and Development AbbVie, biotech, drugs, pharma, pharmaceutical, rheumatoid arthritis

AbbVie posted strong results from its Phase 3 trial into its treatment for rheumatoid arthritis, upadacitinib, but discussions of the …

Sanofi’s arthritis treatment Kevzara secures NICE recommendation

September 25, 2017
Sales and Marketing Kevzara, NICE, Sanofi, pharma, pharmaceutical, rheumatoid arthritis, sarilumab

Sanofi, along with its speciality care global business unit Sanofi Genzyme, are celebrating the news that NICE has passed its …

Questions raised after two deaths in AbbVie arthritis study

September 12, 2017
Manufacturing and Production, Research and Development AbbVie, biotech, drugs, pharma, pharmaceutical, rheumatoid arthritis

AbbVie’s rheumatoid arthritis drug, upadacitinib, is the company’s big plan to manage the inevitable loss of sales from Humira, as …


FDA turns down Janssen’s sirukumab for rheumatoid arthritis

August 3, 2017
Sales and Marketing FDA, Janssen, drugs, life sciences, medicine, pharma, pharmaceuticals, rheumatoid arthritis, sirukumab

Janssen has announced that it has suffered a knockback to its plans to commercialise sirukumab in the US in the …

Latest content